CA2090401A1 - Method of treating viral infection - Google Patents

Method of treating viral infection

Info

Publication number
CA2090401A1
CA2090401A1 CA002090401A CA2090401A CA2090401A1 CA 2090401 A1 CA2090401 A1 CA 2090401A1 CA 002090401 A CA002090401 A CA 002090401A CA 2090401 A CA2090401 A CA 2090401A CA 2090401 A1 CA2090401 A1 CA 2090401A1
Authority
CA
Canada
Prior art keywords
tnf
ligand
residues
binds
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002090401A
Other languages
English (en)
French (fr)
Inventor
Deborah A. Rathjen
Roger Aston
Ian A. Ramshaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals Australia Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2090401A1 publication Critical patent/CA2090401A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002090401A 1990-08-27 1991-08-27 Method of treating viral infection Abandoned CA2090401A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPK197690 1990-08-27
AUPK1976 1990-08-27
PCT/AU1991/000400 WO1992003145A1 (en) 1990-08-27 1991-08-27 Method of treating viral infection

Publications (1)

Publication Number Publication Date
CA2090401A1 true CA2090401A1 (en) 1992-02-28

Family

ID=3774922

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002090401A Abandoned CA2090401A1 (en) 1990-08-27 1991-08-27 Method of treating viral infection

Country Status (4)

Country Link
EP (1) EP0608212A1 (de)
JP (1) JPH06500323A (de)
CA (1) CA2090401A1 (de)
WO (1) WO1992003145A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587457A (en) * 1990-03-12 1996-12-24 Peptide Technology Limited Neutrophil stimulating peptides
US6375928B1 (en) * 1990-03-12 2002-04-23 Peptech Limited Neutrophil stimulating peptides
IT1254315B (it) * 1992-03-27 1995-09-14 Mini Ricerca Scient Tecnolog Anticorpi monoclonali anti-idiotipici diretti contro anticorpi anti-tnf.
ATE172880T1 (de) * 1992-08-28 1998-11-15 Bayer Ag Verwendung von monoklonalen anti-tnf-antikörpern für die behandlung von bakteriellen meningitiden
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
AU2009333883B2 (en) 2008-12-29 2015-05-21 Trevena, Inc. Beta-arrestin effectors and compositions and methods of use thereof
EA201491455A1 (ru) 2012-01-31 2015-01-30 Тревена, Инк. ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AU2015213777A1 (en) 2014-02-07 2016-09-22 Trevena, Inc. Crystalline and amorphous forms of a beta-arrestin effector
JP2017518290A (ja) 2014-05-19 2017-07-06 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． β−アレスチンエフェクターの合成

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03503840A (ja) * 1988-01-15 1991-08-29 セントコアー，インコーポレーテッド 異種連結抗体およびその治療的使用
WO1990001950A1 (en) * 1988-08-19 1990-03-08 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards

Also Published As

Publication number Publication date
EP0608212A4 (de) 1993-10-20
JPH06500323A (ja) 1994-01-13
WO1992003145A1 (en) 1992-03-05
EP0608212A1 (de) 1994-08-03

Similar Documents

Publication Publication Date Title
AU640400B2 (en) Tumour necrosis factor binding ligands
US6451983B2 (en) Tumor necrosis factor antibodies
US6593458B1 (en) Tumor necrosis factor peptide binding antibodies
US7528237B2 (en) Tumour necrosis factor binding ligands
CA2090401A1 (en) Method of treating viral infection
AU654501B2 (en) Method of treating viral infection

Legal Events

Date Code Title Description
FZDE Dead